Shedding light on key pharmacological knowledge and strategies for pediatric atopic dermatitis

References

• Bieber T. Mechanisms of disease. N Engl J Med. 2008;358:1483–1494.
   PubMed Web of Science ®Google Scholar
• Czarnowicki T, He H, Kim H, et al. 074 Evolution of pathologic T-cell subsets in atopic dermatitis from infancy to adulthood. J Invest Dermatol. 2019;139(5):S13.
   PubMed Web of Science ®Google Scholar
• Hanifin JM, Reed ML, Prevalence E, et al. A population-based survey of eczema prevalence in the United States. Dermatitis. 2007;18(2):82–91.
   PubMed Web of Science ®Google Scholar
• Flohr C, Mann J. New insights into the epidemiology of childhood atopic dermatitis. Allergy. 2014;69(1):3–16.
   PubMed Web of Science ®Google Scholar
• Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016 Mar 12;387(10023):1109–1122.
   PubMed Web of Science ®Google Scholar
• Brunner PM, Israel A, Zhang N, et al. Early-onset pediatric atopic dermatitis is characterized by TH2/TH17/TH22-centered inflammation and lipid alterations. J Allergy Clin Immunol. 2018;141(6):2094–2106.
   PubMed Web of Science ®Google Scholar
• Esaki H, Brunner PM, Renert-Yuval Y, et al. Early-onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skin. J Allergy Clin Immunol. 2016;138(6):1639–1651.
   PubMed Web of Science ®Google Scholar
• Czarnowicki T, He H, Canter T, et al. Evolution of pathologic T-cell subsets in patients with atopic dermatitis from infancy to adulthood. J Allergy Clin Immunol. 2020;145(1):215–228.
   PubMed Web of Science ®Google Scholar
• Renert‐Yuval Y, Pavel AB, Bose S, et al. Tape‐strips capture atopic dermatitis‐related changes in non‐lesional skin throughout maturation. Allergy. 2022;77(11): 3445–3447.
   PubMed Web of Science ®Google Scholar
• Renert-Yuval Y, Del Duca E, Pavel AB, et al. The molecular features of normal and atopic dermatitis skin in infants, children, adolescents, and adults. J Allergy Clin Immunol. 2021;148(1):148–163.
   PubMed Web of Science ®Google Scholar
• Zhou L, Leonard A, Pavel AB, et al. Age-specific changes in the molecular phenotype of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2019;144(1):144–156.
   PubMed Web of Science ®Google Scholar
• Silverberg NB. A practical overview of pediatric atopic dermatitis, part 3: differential diagnosis, comorbidities, and measurement of disease burden. Cutis. 2016;97(6):408–412.
   PubMed Web of Science ®Google Scholar
• Blome C, Radtke MA, Eissing L, et al. Quality of life in patients with atopic dermatitis: disease burden, measurement, and treatment benefit. Am J Clin Dermatol. 2016;17(2):163–169.
   PubMed Web of Science ®Google Scholar
• Weidinger S, Simpson EL, Eckert L, et al. The patient-reported disease burden in pediatric patients with atopic dermatitis (AD): a cross-sectional study in the United States (US), Canada, Europe, and Japan. St. Louis, MO: Presented at the San Diego Dermatology Symposium (SDDS 2020); 2020.
   Google Scholar
• Shaw TE, Currie GP, Koudelka CW, et al. Eczema prevalence in the United States: data from the 2003 National survey of children’s health. J Invest Dermatol. 2011;131(1):67–73.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Barbarot S, Gadkari A, et al. Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study. Ann Allergy Asthma Immunol. 2021; e2. 126(4):417–428.
   PubMed Web of Science ®Google Scholar
• Silverberg JI. Public health burden and epidemiology of atopic dermatitis. Dermatol Clin. 2017;35(3):283–289.
   PubMed Web of Science ®Google Scholar
• Hill D, Hosking C. Food allergy and atopic dermatitis in infancy: an epidemiologic study. Pediatr Allergy Immunol. 2004;15(5):421–427.
   PubMed Web of Science ®Google Scholar
• Lowe AJ, Leung DY, Tang ML, et al. The skin as a target for prevention of the atopic march. Ann Allergy Asthma Immunol. 2018;120(2):145–151.
   PubMed Web of Science ®Google Scholar
• Kelleher M, Dunn-Galvin A, Hourihane JOB, et al. RETRACTED: skin barrier dysfunction measured by transepidermal water loss at 2 days and 2 months predates and predicts atopic dermatitis at 1 year. New York, USA: Elsevier; 2015.
   Google Scholar
• Simpson EL, Chalmers JR, Hanifin JM, et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J Allergy Clin Immunol. 2014;134(4):818–823.
   PubMed Web of Science ®Google Scholar
• Chalmers JR, Haines RH, Bradshaw LE, et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet. 2020;395(10228):962–972.
   PubMed Web of Science ®Google Scholar
• Chang Y-S, Trivedi MK, Jha A, et al. Synbiotics for prevention and treatment of atopic dermatitis: a meta-analysis of randomized clinical trials. JAMA Pediatr. 2016;170(3):236–242.
   PubMed Web of Science ®Google Scholar
• Hide D. Early intervention for the prevention of atopic dermatitis. Pediatr Allergy Immunol. 1997;8(1):7–10.
   PubMed Web of Science ®Google Scholar
• Kukkonen K, Savilahti E, Haahtela T, et al. Probiotics and prebiotic galacto-oligosaccharides in the prevention of allergic diseases: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2007;119(1):192–198.
   PubMed Web of Science ®Google Scholar
• Skjerven HO, Rehbinder EM, Vettukattil R, et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet. 2020;395(10228):951–961.
   PubMed Web of Science ®Google Scholar
• Horimukai K, Morita K, Narita M, et al. Application of moisturizer to neonates prevents development of atopic dermatitis. J Allergy Clin Immunol. 2014;134(4):824–830.
   PubMed Web of Science ®Google Scholar
• Bertelsen RJ, Brantsæter AL, Magnus MC, et al. Probiotic milk consumption in pregnancy and infancy and subsequent childhood allergic diseases. J Allergy Clin Immunol. 2014;133(1):165–171.
   PubMed Web of Science ®Google Scholar
• Cao L, Wang L, Yang L, et al. Long-term effect of early-life supplementation with probiotics on preventing atopic dermatitis: a meta-analysis. J Dermatological Treat. 2015;26(6):537–540.
   PubMed Web of Science ®Google Scholar
• Enomoto T, Sowa M, Nishimori K, et al. Effects of bifidobacterial supplementation to pregnant women and infants in the prevention of allergy development in infants and on fecal microbiota. Allergol Int. 2014;63(4):575–585.
   PubMed Web of Science ®Google Scholar
• Akelma AZ, Biten AA. Probiotics and infantile atopic eczema. Pediatric Health Med Ther. 2015;6:147.
   PubMedGoogle Scholar
• Allen SJ, Jordan S, Storey M, et al. Probiotics in the prevention of eczema: a randomised controlled trial. Arch Dis Child. 2014;99(11):1014–1019.
   PubMed Web of Science ®Google Scholar
• Cabana MD, McKean M, Caughey AB, et al. Early probiotic supplementation for eczema and asthma prevention: a randomized controlled trial. Pediatrics. 2017;140:3.
   Web of Science ®Google Scholar
• Del Rosso J, Friedlander SF. Corticosteroids: options in the era of steroid-sparing therapy. J Am Acad Dermatol. 2005;53(1):S50–S58.
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Ahluwalia J, Waldman A, et al. Current guidelines for the evaluation and management of atopic dermatitis–a comparison of the joint task force practice parameter and american academy of dermatology guidelines. Alergologia Polska-Polish Journal of Allergology. 2017;4(4):158–168.
   Google Scholar
• Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and Assessment of Atopic Dermatitis. Journal of the American Academy of Dermatology. 2014;70(2):338–351.
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and Treatment of Atopic Dermatitis with Topical Therapies. Journal of the American Academy of Dermatology. 2014;71(1):116–132.
   Google Scholar
• Diaz A, Guttman-Yassky E. Topical agents for the treatment of atopic dermatitis. Expert Rev Clin Immunol. 2019;15(4):369–382.
   PubMed Web of Science ®Google Scholar
• Saito‐Abe M, Futamura M, Yamamoto‐Hanada K, et al. Topical corticosteroid phobia among caretakers of children with atopic dermatitis: a cross‐sectional study using TOPICOP in Japan. Pediatr Dermatol. 2019;36(3):311–316.
   PubMed Web of Science ®Google Scholar
• Lee JY, Her Y, Kim CW, et al. Topical corticosteroid phobia among parents of children with atopic eczema in Korea. Ann Dermatol. 2015;27(5):499–506.
   PubMed Web of Science ®Google Scholar
• Gustavsen H, Gjersvik P. Topical corticosteroid phobia among parents of children with atopic dermatitis in a semirural area of Norway. J Eur Acad Dermatol Venereol JEADV. 2016;30(1):168.
   PubMed Web of Science ®Google Scholar
• Huang A, Cho C, Leung DY, et al. Atopic dermatitis: early treatment in children. Current Treatment Options in Allergy. 2017;4(3):355–369.
   PubMedGoogle Scholar
• Chiricozzi A, Comberiati P, D’Auria E, et al. Topical corticosteroids for pediatric atopic dermatitis: thoughtful tips for practice. Pharmacol Res. 2020;158:104878.
   PubMed Web of Science ®Google Scholar
• Glazenburg EJ, Wolkerstorfer A, Gerretsen AL, et al. Efficacy and safety of fluticasone propionate 0.005% ointment in the long‐term maintenance treatment of children with atopic dermatitis: differences between boys and girls? Pediatr Allergy Immunol. 2009;20(1):59–66.
   PubMed Web of Science ®Google Scholar
• Paller AS, Mcalister RO, Doyle JJ, et al. Perceptions of physicians and pediatric patients about atopic dermatitis, its impact, and its treatment. Clin Pediatr (Phila). 2002;41(5):323–332.
   PubMed Web of Science ®Google Scholar
• Horii KA, Simon SD, Liu DY, et al. Atopic dermatitis in children in the United States, 1997–2004: visit trends, patient and provider characteristics, and prescribing patterns. Pediatrics. 2007;120(3):e527–e534.
   PubMed Web of Science ®Google Scholar
• Bass AM, Anderson KL, Feldman SR. Interventions to increase treatment adherence in pediatric atopic dermatitis: a systematic review. J Clin Med. 2015;4(2):231–242.
   PubMed Web of Science ®Google Scholar
• Grillo M, Gassner L, Marshman G, et al. Pediatric atopic eczema: the impact of an educational intervention. Pediatr Dermatol. 2006;23(5):428–436.
   PubMed Web of Science ®Google Scholar
• Cheong JYV, Hie SL, Koh EW, et al. Impact of pharmacists’ counseling on caregiver’s knowledge in the management of pediatric atopic dermatitis. Pediatr Dermatol. 2019;36(1):105–109.
   PubMed Web of Science ®Google Scholar
• Raimer SS. Managing pediatric atopic dermatitis. Clin Pediatr (Phila). 2000;39(1):1–14.
   PubMed Web of Science ®Google Scholar
• Piacquadio D. Topical corticosteroids in clinical practice: focus on fluticasone propionate. Cutis. 1996;57(2 Suppl):4–9.
   PubMedGoogle Scholar
• West DP, Worobec S, Solomon LM. Pharmacology and toxicology of infant skin. J Invest Dermatol. 1981;76(3):147–150.
   PubMed Web of Science ®Google Scholar
• Turpeinen M. Influence of age and severity of dermatitis on the percutaneous absorption of hydrocortisone in children. Br J Dermatol. 1988;118(4):517–522.
   PubMed Web of Science ®Google Scholar
• Brazzini B, Pimpinelli N. New and established topical corticosteroids in dermatology. Am J Clin Dermatol. 2002;3(1):47–58.
   PubMedGoogle Scholar
• El Hachem M, Gesualdo F, Ricci G, et al. Topical corticosteroid phobia in parents of pediatric patients with atopic dermatitis: a multicentre survey. Ital J Pediatr. 2017;43(1):1–6.
   PubMedGoogle Scholar
• Heickman LKW, Ghajar LD, Conaway M, et al. Evaluation of hypothalamic-pituitary-adrenal axis suppression following cutaneous use of topical corticosteroids in children: a meta-analysis. Hormone Res Paediatrics. 2018;89:389–396.
   PubMed Web of Science ®Google Scholar
• Siegfried EC, Jaworski JC, Kaiser JD, et al. Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis. BMC pediatrics. 2016;16(1):1–15.
   Google Scholar
• PROTOPIC® (tacrolimus) label
   Google Scholar
• Luger T, Boguniewicz M, Carr W, et al. Pimecrolimus in atopic dermatitis: consensus on safety and the need to allow use in infants. Pediatr Allergy Immunol. 2015;26(4):306–315.
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and Treatment of Atopic Dermatitis with Topical Therapies. Journal of the American Academy of Dermatology. 2014 Jul;71(1):116–132.
   Google Scholar
• Simpson EL. Atopic dermatitis: a review of topical treatment options. Curr Med Res Opin. 2010;26(3):633–640.
   PubMed Web of Science ®Google Scholar
• Bornhövd E, Burgdorf WH, Wollenberg A. Macrolactam immunomodulators for topical treatment of inflammatory skin diseases. J Am Acad Dermatol. 2001;45(5):736–743.
   PubMed Web of Science ®Google Scholar
• Ruzicka T, Assmann T, Homey B. Tacrolimus: the drug for the turn of the millennium? Arch Dermatol. 1999;135(5):574–580.
   PubMedGoogle Scholar
• Sehgal VN, Srivastava G, Dogra S. Tacrolimus in dermatology—pharmacokinetics, mechanism of action, drug interactions, dosages, and side effects: part I. SKINmed: Dermatology for the Clinician. 2008;7(1):27–30.
   Google Scholar
• de Paulis A, Stellato C, Cirillo R, et al. Anti-inflammatory effect of FK-506 on human skin mast cells. J Invest Dermatol. 1992;99(6):723–728.
   PubMed Web of Science ®Google Scholar
• Kondo Y, Nakajima Y, Komatsubara R, et al. Short‐term efficacy of tacrolimus ointment and impact on quality of life. Pediatr Int. 2009;51(3):385–389.
   PubMed Web of Science ®Google Scholar
• Paller A, Eichenfield LF, Leung DY, et al. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol. 2001;44(1):S47–S57.
   PubMed Web of Science ®Google Scholar
• Takeuchi S, Saeki H, Tokunaga S, et al. A randomized, open-label, multicenter trial of topical tacrolimus for the treatment of pruritis in patients with atopic dermatitis. Ann Dermatol. 2012;24(2):144–150.
   PubMed Web of Science ®Google Scholar
• Ohtsuki M, Morimoto H, Nakagawa H. Tacrolimus ointment for the treatment of adult and pediatric atopic dermatitis: review on safety and benefits. J Dermatol. 2018;45(8):936–942.
   PubMed Web of Science ®Google Scholar
• Yan J, SL CHEN, Xl WANG, et al. Meta‐analysis of tacrolimus ointment for atopic dermatitis in pediatric patients. Pediatr Dermatol. 2008;25(1):117–120.
   PubMed Web of Science ®Google Scholar
• Mmy E-B, Bosseila MA-W, Mashaly HM, et al. Topical calcineurin inhibitors in atopic dermatitis: a systematic review and meta-analysis. J Dermatol Sci. 2009;54(2):76–87.
   PubMed Web of Science ®Google Scholar
• Breuer K, Werfel T, Kapp A. Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis. Am J Clin Dermatol. 2005;6(2):65–77.
   PubMed Web of Science ®Google Scholar
• Boguniewicz M, Fiedler VC, Raimer S, et al. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. J Allergy Clin Immunol. 1998;102(4):637–644.
   PubMed Web of Science ®Google Scholar
• Reitamo S, Rustin M, Ruzicka T, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol. 2002;109(3):547–555.
   PubMed Web of Science ®Google Scholar
• Kang S, Lucky AW, Pariser D, et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol. 2001;44(1):S58–S64.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Gower T. A safety assessment of topical calcineurin inhibitors in the treatment of atopic dermatitis. Medscape J Med. 2006;8(4):8.
   Google Scholar
• Wahn U, Bos JD, Goodfield M, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics. 2002;110(1):e2–e2.
   PubMed Web of Science ®Google Scholar
• Stiehm ER, Roberts RL, Kaplan MS, et al. Pneumococcal seroconversion after vaccination for children with atopic dermatitis treated with tacrolimus ointment. J Am Acad Dermatol. 2005;53(2):S206–S213.
   PubMed Web of Science ®Google Scholar
• Papp KA, Breuer K, Meurer M, et al. Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination. J Am Acad Dermatol. 2005;52(2):247–253.
   PubMed Web of Science ®Google Scholar
• Ring J, Möhrenschlager M, The HV. US FDA ‘Black Box’warning for topical calcineurin inhibitors. Drug Saf. 2008;31(3):185–198.
   PubMed Web of Science ®Google Scholar
• Fonacier L, Charlesworth EN, Spergel JM, et al. The black box warning for topical calcineurin inhibitors: looking outside the box. Ann Allergy Asthma Immunol. 2006;97(1):117–120.
   PubMed Web of Science ®Google Scholar
• Qureshi AA, Fischer MA. Topical calcineurin inhibitors for atopic dermatitis: balancing clinical benefit and possible risks. Arch Dermatol. 2006;142(5):633–637.
   PubMedGoogle Scholar
• Fonacier L, Spergel J, Charlesworth EN, et al. Report of the topical calcineurin inhibitor task force of the American college of allergy, asthma and immunology and the American academy of allergy, asthma and immunology. Journal of allergy and clinical immunology. 2005;115(6):1249–1253.
   Google Scholar
• Margolis DJ, Abuabara K, Hoffstad OJ, et al. Association between malignancy and topical use of pimecrolimus. JAMA Dermatol. 2015;151(6):594–599.
   PubMed Web of Science ®Google Scholar
• Paller AS, Fölster-Holst R, Chen SC, et al. No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis. J Am Acad Dermatol. 2020;83(2):375–381.
   PubMed Web of Science ®Google Scholar
• Legendre L, Barnetche T, Mazereeuw-Hautier J, et al. Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: a systematic review and meta-analysis. J Am Acad Dermatol. 2015;72(6):992–1002.
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Call RS, Forsha DW, et al. Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis. J Am Acad Dermatol. 2017;77(4):641–649.
   PubMed Web of Science ®Google Scholar
• Guttman‐Yassky E, Hanifin JM, Boguniewicz M, et al. The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition. Exp Dermatol. 2019;28(1):3–10.
   PubMed Web of Science ®Google Scholar
• Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016;75(3):494–503.
   PubMed Web of Science ®Google Scholar
• Yosipovitch G, Gold LF, Lebwohl MG, et al. Early relief of pruritus in atopic dermatitis with crisaborole ointment, a non-steroidal, phosphodiesterase 4 inhibitor. Acta Derm Venereol. 2018;98(5):484–489.
   PubMed Web of Science ®Google Scholar
• Spelman L, Spellman M, Hughes M, et al. A Phase 2, randomized, controlled, dose-ranging study evaluating crisaborole topical ointment, 0.5% and 2% in adolescents with mild to moderate atopic dermatitis. J Drugs Dermatol. 2015;14(12):1394–1399.
   PubMed Web of Science ®Google Scholar
• Su JC, Spelman LJ, Eichenfield LF, et al. Efficacy And safety of crisaborole in patients aged 3 months to 17 years with mild-to-moderate atopic dermatitis. American academy of Pediatrics Itasca. IL, USA; 2021.
   Google Scholar
• Zane L, Chanda S, Jarnagin K, et al. Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies. Immunotherapy. 2016;8(8):853–866.
   PubMed Web of Science ®Google Scholar
• Dina Coronado B, Zane LT, Coronado D. Crisaborole topical ointment, 2%: a nonsteroidal, topical, anti-inflammatory phosphodiesterase 4 inhibitor in clinical development for the treatment of atopic dermatitis. J Drugs Dermatol. 2016;15(4):390–396.
   PubMed Web of Science ®Google Scholar
• D’Ippolito D, Dupilumab PM. (Dupixent): an interleukin-4 receptor antagonist for atopic dermatitis. Pharm Ther. 2018;43(9):532.
   Google Scholar
• Kuchner M, Nemmer JM, Werfel T, et al. Dysbalance between the immune system and skin microbiome in chronic inflammatory dermatoses. Venerologie und Verwandte Gebiete: Der Hautarzt; Zeitschrift fur Dermatologie; 2021.
   Google Scholar
• Guttman-Yassky E, Bissonnette R, Ungar B, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;143(1):155–172.
   PubMed Web of Science ®Google Scholar
• de Bruin-Weller M, Graham N, Pirozzi G, et al. Could conjunctivitis in patients with atopic dermatitis treated with dupilumab be caused by colonization with Demodex and increased interleukin-17 levels?: reply from the authors. Br J Dermatol. 2018;178(5):1220–1221.
   PubMed Web of Science ®Google Scholar
• Paller A, Siegfried E, Simpson E, et al. A phase 2, open‐label study of single‐dose dupilumab in children aged 6 months to< 6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy. J Eur Acad Dermatol Venereol. 2021;35(2):464–475.
   PubMed Web of Science ®Google Scholar
• Julie Block NP, George D MD, Yancopoulos. Press Release: FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis. Paris and Tarrytown, N.Y.: Sanofi. 2022.
   Google Scholar
• Igelman S, Kurta AO, Sheikh U, et al. Off-label use of dupilumab for pediatric patients with atopic dermatitis: a multicenter retrospective review. J Am Acad Dermatol. 2020;82(2):407–411.
   PubMed Web of Science ®Google Scholar
• Licari A, Castagnoli R, Marseglia A, et al. Dupilumab to treat type 2 inflammatory diseases in children and adolescents. Pediatr Drugs. 2020;22(3):295–310.
   PubMed Web of Science ®Google Scholar
• Cork M, Thaçi D, Eichenfield L, et al. Dupilumab provides favourable long‐term safety and efficacy in children aged≥ 6 to< 12 years with uncontrolled severe atopic dermatitis: results from an open‐label phase IIa study and subsequent phase III open‐label extension study. Br J Dermatol. 2021;184(5):857–870.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156(1):44–56.
   PubMed Web of Science ®Google Scholar
• Treister AD, Lio PA. Long‐term off‐label dupilumab in pediatric atopic dermatitis: a case series. Pediatr Dermatol. 2019;36(1):85–88.
   PubMed Web of Science ®Google Scholar
• Fargnoli M, Esposito M, Ferrucci S, et al. Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis. J Dermatological Treat. 2021;32(5):507–513.
   PubMed Web of Science ®Google Scholar
• Halling A-S, Loft N, Silverberg JI, et al. Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis. J Am Acad Dermatol. 2021;84(1):139–147.
   PubMed Web of Science ®Google Scholar
• De Wijs L, Bosma A, Erler N, et al. Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice data. Br J Dermatol. 2020;182(2):418–426.
   PubMed Web of Science ®Google Scholar
• Julie Block NP, George D MD, Yancopoulos. Press Release: FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis 2022 [Jul/29/2022]. Available from: https://www.sanofi.com/en/media-room/press-releases/2022/2022-06-07-20-45-00-2458243#:~:text=June%207%2C%202022.,those%20therapies%20are%20not%20advisable.
   Google Scholar
• U.S. Food and Drug Administration, HIGHLIGHTS OF PRESCRIBING INFORMATION DUPIXENT® (dupilumab) injection, for subcutaneous use Initial U.S. Approval. Vol. 2019. Maryland, USA: FDA. 2017.
   Google Scholar
• Busse WW, Maspero JF, Rabe KF, et al. Liberty Asthma QUEST: phase 3 randomized, double-blind, placebo-controlled, parallel-group study to evaluate dupilumab efficacy/safety in patients with uncontrolled, moderate-to-severe asthma. Adv Ther. 2018;35(5):737–748.
   PubMed Web of Science ®Google Scholar
• Maspero J, Fitzgerald M, Pavord I, et al. Dupilumab reduces severe exacerbation rate and improves lung function in adolescent patients with uncontrolled, moderate-to-severe asthma: from the liberty asthma quest study. Chest. 2018;154(4):25A–27A.
   Web of Science ®Google Scholar
• Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486–2496.
   PubMed Web of Science ®Google Scholar
• Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475–2485.
   PubMed Web of Science ®Google Scholar
• FDA Approves First. Treatment for Eosinophilic Esophagitis, a Chronic Immune Disorder. Maryland, USA: FDA. 2022.
   Google Scholar
• Bachert C, Mannent L, Naclerio RM, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. Jama. 2016;315(5):469–479.
   PubMed Web of Science ®Google Scholar
• Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638–1650.
   PubMed Web of Science ®Google Scholar
• Jia Q-N, Qiao J, Fang K, et al. Ocular adverse effects in atopic dermatitis patients treated with dupilumab: a bibliometric analysis. Fogagnolo, Paolo . In: Frontiers in medicine. Lausanne: Front Med. 2022. p. 9.
   Google Scholar
• Guttman-Yassky E, Blauvelt A, Eichenfield LF, et al. Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial. JAMA Dermatol. 2020;156(4):411–420.
   PubMed Web of Science ®Google Scholar
• Lilly’s lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic dermatitis in two Phase 3 trials 2021. [cited 2022 May 26]. Available from: https://investor.lilly.com/news-releases/news-release-details/lillys-lebrikizumab-significantly-improved-skin-clearance-and
   Google Scholar
• Freitas E, Guttman-Yassky E, Torres T. Tralokinumab for the treatment of atopic dermatitis. Am J Clin Dermatol. 2021;22(5):625–638.
   PubMed Web of Science ®Google Scholar
• Popovic B, Breed J, Rees D, et al. Structural characterisation reveals mechanism of IL-13-neutralising monoclonal antibody tralokinumab as inhibition of binding to IL-13Rα1 and IL-13Rα2. J Mol Biol. 2017;429(2):208–219.
   PubMed Web of Science ®Google Scholar
• Paller A, Blauvelt A, Soong W, et al. Efficacy and safety of tralokinumab in adolescents with moderate-to-severe atopic dermatitis: results of the phase 3 ECZTRA 6 trial. Age (Omaha). 2021;12:17.
   Google Scholar
• Kelly KA, Perche PO, Feldman SR. Therapeutic potential of tralokinumab in the treatment of atopic dermatitis: a review on the emerging clinical data. Clin Cosmet Investig Dermatol. 2022;15:1037.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Blauvelt A, Guttman‐Yassky E, et al. Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184(3):437–449.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Beck L, de Bruin Weller M, et al. Conjunctivitis in adult patients with moderate‐to‐severe atopic dermatitis: results from five tralokinumab clinical trials. Br J Dermatol. 2022;186(3):453–465.
   PubMed Web of Science ®Google Scholar
• Chovatiya R, Paller AS. JAK inhibitors in the treatment of atopic dermatitis. J Allergy Clin Immunol. 2021;148(4):927–940.
   PubMed Web of Science ®Google Scholar
• U.S. FDA Approves RINVOQ® (upadacitinib) to treat adults and children 12 years and older with refractory, moderate to severe atopic dermatitis 2022. [cited 2022 Aug 6]. Available from: https://news.abbvie.com/news/press-releases/us-fda-approves-rinvoq-upadacitinib-to-treat-adults-and-children-12-years-and-older-with-refractory-moderate-to-severe-atopic-dermatitis.htm
   Google Scholar
• Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021;397(10290):2151–2168.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, de Bruin-Weller M, Bieber T, et al. Upadacitinib plus topical corticosteroids in atopic dermatitis: week 52 AD Up study results. J Allergy Clin Immunol. 2022;149(3):977–987.
   PubMed Web of Science ®Google Scholar
• HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to useOPZELURA cream safely and effectively. [cited 2022 May 2]. Available from: https://www.opzelura.com/prescribing-information.pdf
   Google Scholar
• Papp K, Szepietowski JC, Kircik L, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies. J Am Acad Dermatol. 2021;85(4):863–872.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Szepietowski JC, Papp K, et al. 26884 Ruxolitinib cream rapidly decreases pruritus in atopic dermatitis: pooled results from two phase 3 studies. J Am Acad Dermatol. 2021;85(3):AB121.
   Web of Science ®Google Scholar
• Simpson EL, Boguniewicz M, Thaçi D, et al. 26887 Effect of ruxolitinib cream on sleep disturbance and sleep impairment: pooled analysis from two randomized phase 3 studies. J Am Acad Dermatol. 2021;85(3):AB121.
   Web of Science ®Google Scholar
• Eichenfield LF, Silverberg JI, Kuligowski ME, et al. 28200 Effects of ruxolitinib cream on work productivity and activity impairment in patients with atopic dermatitis: pooled results from two phase 3 studies. J Am Acad Dermatol. 2021;85(3):AB179.
   Web of Science ®Google Scholar
• Totri CR, Eichenfield LF, Logan K, et al. Prescribing practices for systemic agents in the treatment of severe pediatric atopic dermatitis in the US and Canada: the PeDRA TREAT survey. J Am Acad Dermatol. 2017;76(2):281–285.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Bruin-Weller M, Flohr C, et al. When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. J Am Acad Dermatol. 2017;77(4):623–633.
   PubMed Web of Science ®Google Scholar
• Davari DR, Nieman EL, McShane DB, et al. Current perspectives on the systemic management of atopic dermatitis. J Asthma Allergy. 2021;14:595.
   PubMed Web of Science ®Google Scholar
• Deo M, Yung A, Hill S, et al. Methotrexate for treatment of atopic dermatitis in children and adolescents. Int J Dermatol. 2014;53(8):1037–1041.
   PubMed Web of Science ®Google Scholar
• Anderson K, Putterman E, Rogers RS, et al. Treatment of severe pediatric atopic dermatitis with methotrexate: a retrospective review. Pediatr Dermatol. 2019;36(3):298–302.
   PubMed Web of Science ®Google Scholar
• Dvorakova V, O’Regan GM, Irvine AD. Methotrexate for severe childhood atopic dermatitis: clinical experience in a tertiary center. Pediatr Dermatol. 2017;34(5):528–534.
   PubMed Web of Science ®Google Scholar
• Wolverton SE, Wu JJ. Comprehensive dermatologic drug therapy. Philadephia , USA: Elsevier Health Sciences; 2019.
   Google Scholar
• Caufield M, Tom WL. Oral azathioprine for recalcitrant pediatric atopic dermatitis: clinical response and thiopurine monitoring. J Am Acad Dermatol. 2013;68(1):29–35.
   PubMed Web of Science ®Google Scholar
• Murphy LA, Atherton D. A retrospective evaluation of azathioprine in severe childhood atopic eczema, using thiopurine methyltransferase levels to exclude patients at high risk of myelosuppression. Br J Dermatol. 2002;147(2):308–315.
   PubMed Web of Science ®Google Scholar
• Waxweiler WT, Agans R, Morrell DS. Systemic treatment of pediatric atopic dermatitis with azathioprine and mycophenolate mofetil. Pediatr Dermatol. 2011;28(6):689–694.
   PubMed Web of Science ®Google Scholar
• Khattri S, Shemer A, Rozenblit M, et al. Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology. J Allergy Clin Immunol. 2014;133(6):1626–1634.
   PubMed Web of Science ®Google Scholar
• Berth-Jones J, Finlay AY, Zaki I, et al. Cyclosporine in severe childhood atopic dermatitis: a multicenter study. J Am Acad Dermatol. 1996;34(6):1016–1021.
   PubMed Web of Science ®Google Scholar
• Sibbald C, Pope E, Ho N, et al. Retrospective review of relapse after systemic cyclosporine in children with atopic dermatitis. Pediatr Dermatol. 2015;32(1):36–40.
   PubMed Web of Science ®Google Scholar
• Garrido Colmenero C, Blasco Morente G, Tercedor Sánchez J. Oral cyclosporine weekend therapy: a new maintenance therapeutic option in patients with severe atopic dermatitis. Pediatr Dermatol. 2015;32(4):551–552.
   PubMed Web of Science ®Google Scholar
• Ricci G, Dondi A, Patrizi A, et al. Systemic therapy of atopic dermatitis in children. Drugs. 2009;69(3):297–306.
   PubMed Web of Science ®Google Scholar
• Slater NA, Morrell DS. Systemic therapy of childhood atopic dermatitis. Clin Dermatol. 2015;33(3):289–299.
   PubMed Web of Science ®Google Scholar
• HIGHLIGHTS OF PRESCRIBING INFORMATION CELLCEPT (mycophenolate mofetil) capsules, for oral use
   Google Scholar
• Neuber K, Schwartz I, Itschert G, et al. Treatment of atopic eczema with oral mycophenolate mofetil. Br J Dermatol. 2000;143(2):385–391.
   PubMed Web of Science ®Google Scholar
• Heller M, Shin H, Orlow S, et al. Mycophenolate mofetil for severe childhood atopic dermatitis: experience in 14 patients. Br J Dermatol. 2007;157(1):127–132.
   PubMed Web of Science ®Google Scholar
• Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil. Drug Saf. 2001;24(9):645–663.
   PubMed Web of Science ®Google Scholar